User profiles for A. Quan

QUAN-FU AN(安全福)

BEIJING UNIVERSITY OF TECHNOLOGY
Verified email at bjut.edu.cn
Cited by 11471

Recent development of fiber-optic chemical sensors and biosensors: Mechanisms, materials, micro/nano-fabrications and applications

M Yin, B Gu, QF An, C Yang, YL Guan… - Coordination Chemistry …, 2018 - Elsevier
The Internet-of-Things (IoT) has witnessed exponential growth over the past decade and will
significantly reshape human life from every aspect, eg, defense, environmental monitoring, …

Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists

A Quan - Early human development, 2006 - Elsevier
The renin–angiotensin system plays an important role in the regulation of blood pressure.
The use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers both …

Cross-Linking with Diamine Monomers To Prepare Composite Graphene Oxide-Framework Membranes with Varying d-Spacing

WS Hung, CH Tsou, M De Guzman, QF An… - Chemistry of …, 2014 - ACS Publications
Three diamine monomers (ethylenediamine, butylenediamine, and p-phenylenediamine)
were selected for cross-linking graphene oxide (GO) to prepare composite graphene oxide-…

Graphene oxide membranes with stable porous structure for ultrafast water transport

WH Zhang, MJ Yin, Q Zhao, CG Jin, N Wang… - Nature …, 2021 - nature.com
The robustness of carbon nanomaterials and their potential for ultrahigh permeability has
drawn substantial interest for separation processes. However, graphene oxide membranes (…

Fabrication of hydrothermally reduced graphene oxide/chitosan composite membranes with a lamellar structure on methanol dehydration

WS Hung, SM Chang, RLG Lecaros, YL Ji, QF An… - Carbon, 2017 - Elsevier
Reduced graphene oxide (rGO) has been prepared through hydrothermal reduction, an
environmentally safe reduction of graphene oxide (GO). rGO is used to fabricate a highly …

Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized …

…, AT Yan, T Mason, V Garg, H Teoh, F Zuo, A Quan… - Circulation, 2019 - Am Heart Assoc
Background: SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events
in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown…

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

F Lovren, Y Pan, A Quan, H Teoh… - American Journal …, 2008 - journals.physiology.org
The endothelium plays a central role in the maintenance of vascular homeostasis. One of
the main effectors of endothelial dysfunction is ANG II, and pharmacological approaches to …

MicroRNA-145 targeted therapy reduces atherosclerosis

F Lovren, YI Pan, A Quan, KK Singh, PC Shukla… - Circulation, 2012 - Am Heart Assoc
Background— MicroRNA are essential posttranscriptional modulators of gene expression
implicated in various chronic diseases. Because microRNA-145 is highly expressed in …

Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease

…, PW Connelly, RE Gilbert, N Shehata, A Quan… - Circulation, 2020 - Am Heart Assoc
A, EPO levels in patients receiving empagliflozin 10 mg daily (red circles) or placebo (blue
squares) plotted as mean±95% CIs. Adjusted differences are betweengroup differences in …

Prenatal dexamethasone programs hypertension and renal injury in the rat

LA Ortiz, A Quan, F Zarzar, A Weinberg, M Baum - Hypertension, 2003 - Am Heart Assoc
Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary
development. The purpose of the present study was to determine if prenatal dexamethasone …